A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2), in Combination with Other Agents for Metastatic Prostate Cancer

2022-503132-14-00 Protocol 78278343PCR1003 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 30 Jun 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol 78278343PCR1003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 178
Countries 1
Sites 4

Metastatic Prostate Cancer

Key facts

Sponsor
Janssen - Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
30 Jun 2025 → ongoing
Decision date (initial)
2025-03-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic Prostate Cancer

VersionLevelCodeTermSystem organ class
27.0 PT 10036909 Prostate cancer metastatic 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen - Cilag International

Sponsor organisation
Janssen - Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen - Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen - Cilag International
Contact name
CTIS Point of Contact

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 18 4
Rest of world
United States, Australia
160

Investigational sites

Spain

4 sites · Ongoing, recruiting
Hospital Universitario 12 De Octubre
Oncology Service, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario Hm Sanchinarro
Oncology Service, Calle Ona 10, 28050, Madrid
Hospital Universitari Vall D Hebron
Oncology Service, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncology Service, Avenida De Los Reyes Catolicos 2, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-06-30 2025-06-30

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-26 Spain Acceptable
2025-03-06
2025-03-10
2 SUBSTANTIAL MODIFICATION SM-1 2025-04-14 Spain Acceptable
2025-04-30
2025-05-20
3 SUBSTANTIAL MODIFICATION SM-2 2025-09-04 Spain Acceptable
2025-10-15
2025-10-20
4 SUBSTANTIAL MODIFICATION SM-3 2026-03-26 Spain Acceptable
2026-06-04
2026-06-05